vs
HALOZYME THERAPEUTICS, INC.（HALO）与NEUROCRINE BIOSCIENCES INC（NBIX）财务数据对比。点击上方公司名可切换其他公司
NEUROCRINE BIOSCIENCES INC的季度营收约是HALOZYME THERAPEUTICS, INC.的1.8倍（$805.5M vs $451.8M）。NEUROCRINE BIOSCIENCES INC净利率更高（19.1% vs -31.3%，领先50.4%）。HALOZYME THERAPEUTICS, INC.同比增速更快（51.6% vs 28.3%）。NEUROCRINE BIOSCIENCES INC自由现金流更多（$386.0M vs $217.6M）。过去两年HALOZYME THERAPEUTICS, INC.的营收复合增速更高（51.9% vs 25.0%）
Halozyme Therapeutics是一家美国生物技术企业，专注于肿瘤领域创新疗法研发，核心管线均针对肿瘤微环境进行靶向干预，致力于为全球癌症患者提供更安全高效的治疗选择。
Neurocrine Biosciences是1992年成立的美国生物制药企业，总部位于加利福尼亚州圣地亚哥，截至2024年10月首席执行官为Kyle Gano。公司专注于神经及内分泌相关疾病的疗法研发，旗下药物缬苯那嗪（商品名Ingrezza）于2017年获美国批准，用于治疗成人迟发性运动障碍。
HALO vs NBIX — 直观对比
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $451.8M | $805.5M |
| 净利润 | $-141.6M | $153.7M |
| 毛利率 | 82.6% | 97.8% |
| 营业利润率 | -20.6% | 26.2% |
| 净利率 | -31.3% | 19.1% |
| 营收同比 | 51.6% | 28.3% |
| 净利润同比 | -203.3% | 49.1% |
| 每股收益（稀释后） | $-1.13 | $1.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $451.8M | $805.5M | ||
| Q3 25 | $354.3M | $794.9M | ||
| Q2 25 | $325.7M | $687.5M | ||
| Q1 25 | $264.9M | $572.6M | ||
| Q4 24 | $298.0M | $627.7M | ||
| Q3 24 | $290.1M | $622.1M | ||
| Q2 24 | $231.4M | $590.2M | ||
| Q1 24 | $195.9M | $515.3M |
| Q4 25 | $-141.6M | $153.7M | ||
| Q3 25 | $175.2M | $209.5M | ||
| Q2 25 | $165.2M | $107.5M | ||
| Q1 25 | $118.1M | $7.9M | ||
| Q4 24 | $137.0M | $103.1M | ||
| Q3 24 | $137.0M | $129.8M | ||
| Q2 24 | $93.2M | $65.0M | ||
| Q1 24 | $76.8M | $43.4M |
| Q4 25 | 82.6% | 97.8% | ||
| Q3 25 | 84.4% | 98.2% | ||
| Q2 25 | 85.8% | 98.4% | ||
| Q1 25 | 81.7% | 98.4% | ||
| Q4 24 | 85.9% | 98.5% | ||
| Q3 24 | 83.0% | 98.7% | ||
| Q2 24 | 82.9% | 98.4% | ||
| Q1 24 | 85.5% | 98.5% |
| Q4 25 | -20.6% | 26.2% | ||
| Q3 25 | 61.5% | 30.1% | ||
| Q2 25 | 62.2% | 21.2% | ||
| Q1 25 | 53.4% | 4.1% | ||
| Q4 24 | 58.9% | 22.6% | ||
| Q3 24 | 56.3% | 29.5% | ||
| Q2 24 | 50.7% | 24.6% | ||
| Q1 24 | 48.8% | 19.3% |
| Q4 25 | -31.3% | 19.1% | ||
| Q3 25 | 49.5% | 26.4% | ||
| Q2 25 | 50.7% | 15.6% | ||
| Q1 25 | 44.6% | 1.4% | ||
| Q4 24 | 46.0% | 16.4% | ||
| Q3 24 | 47.2% | 20.9% | ||
| Q2 24 | 40.3% | 11.0% | ||
| Q1 24 | 39.2% | 8.4% |
| Q4 25 | $-1.13 | $1.49 | ||
| Q3 25 | $1.43 | $2.04 | ||
| Q2 25 | $1.33 | $1.06 | ||
| Q1 25 | $0.93 | $0.08 | ||
| Q4 24 | $1.06 | $1.00 | ||
| Q3 24 | $1.05 | $1.24 | ||
| Q2 24 | $0.72 | $0.63 | ||
| Q1 24 | $0.60 | $0.42 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $133.8M | $713.0M |
| 总债务越低越好 | $2.1B | — |
| 股东权益账面价值 | $48.8M | $3.3B |
| 总资产 | $2.5B | $4.6B |
| 负债/权益比越低杠杆越低 | 43.89× | — |
8季度趋势，按日历期对齐
| Q4 25 | $133.8M | $713.0M | ||
| Q3 25 | $419.7M | $340.2M | ||
| Q2 25 | $61.9M | $264.0M | ||
| Q1 25 | $176.3M | $194.1M | ||
| Q4 24 | $115.8M | $233.0M | ||
| Q3 24 | $154.3M | $349.1M | ||
| Q2 24 | $187.9M | $139.7M | ||
| Q1 24 | $164.6M | $396.3M |
| Q4 25 | $2.1B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.5B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.5B | — |
| Q4 25 | $48.8M | $3.3B | ||
| Q3 25 | $503.9M | $3.0B | ||
| Q2 25 | $332.7M | $2.7B | ||
| Q1 25 | $482.3M | $2.5B | ||
| Q4 24 | $363.8M | $2.6B | ||
| Q3 24 | $452.7M | $2.7B | ||
| Q2 24 | $289.4M | $2.5B | ||
| Q1 24 | $177.8M | $2.4B |
| Q4 25 | $2.5B | $4.6B | ||
| Q3 25 | $2.2B | $4.3B | ||
| Q2 25 | $2.1B | $3.9B | ||
| Q1 25 | $2.2B | $3.7B | ||
| Q4 24 | $2.1B | $3.7B | ||
| Q3 24 | $2.1B | $3.5B | ||
| Q2 24 | $2.0B | $3.3B | ||
| Q1 24 | $1.8B | $3.5B |
| Q4 25 | 43.89× | — | ||
| Q3 25 | 3.00× | — | ||
| Q2 25 | 4.54× | — | ||
| Q1 25 | 3.13× | — | ||
| Q4 24 | 4.14× | — | ||
| Q3 24 | 3.32× | — | ||
| Q2 24 | 5.19× | — | ||
| Q1 24 | 8.44× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $219.0M | $388.4M |
| 自由现金流经营现金流 - 资本支出 | $217.6M | $386.0M |
| 自由现金流率自由现金流/营收 | 48.2% | 47.9% |
| 资本支出强度资本支出/营收 | 0.3% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 2.53× |
| 过去12个月自由现金流最近4个季度 | $644.6M | $743.9M |
8季度趋势，按日历期对齐
| Q4 25 | $219.0M | $388.4M | ||
| Q3 25 | $178.6M | $227.5M | ||
| Q2 25 | $99.7M | $102.0M | ||
| Q1 25 | $154.2M | $64.8M | ||
| Q4 24 | $178.5M | $242.5M | ||
| Q3 24 | $115.4M | $158.0M | ||
| Q2 24 | $55.8M | $64.6M | ||
| Q1 24 | $129.4M | $130.3M |
| Q4 25 | $217.6M | $386.0M | ||
| Q3 25 | $175.6M | $214.3M | ||
| Q2 25 | $98.1M | $89.5M | ||
| Q1 25 | $153.3M | $54.1M | ||
| Q4 24 | $175.4M | $235.2M | ||
| Q3 24 | $113.9M | $149.9M | ||
| Q2 24 | $53.2M | $53.0M | ||
| Q1 24 | $125.9M | $119.1M |
| Q4 25 | 48.2% | 47.9% | ||
| Q3 25 | 49.6% | 27.0% | ||
| Q2 25 | 30.1% | 13.0% | ||
| Q1 25 | 57.9% | 9.4% | ||
| Q4 24 | 58.9% | 37.5% | ||
| Q3 24 | 39.3% | 24.1% | ||
| Q2 24 | 23.0% | 9.0% | ||
| Q1 24 | 64.3% | 23.1% |
| Q4 25 | 0.3% | 0.3% | ||
| Q3 25 | 0.9% | 1.7% | ||
| Q2 25 | 0.5% | 1.8% | ||
| Q1 25 | 0.4% | 1.9% | ||
| Q4 24 | 1.0% | 1.2% | ||
| Q3 24 | 0.5% | 1.3% | ||
| Q2 24 | 1.1% | 2.0% | ||
| Q1 24 | 1.8% | 2.2% |
| Q4 25 | — | 2.53× | ||
| Q3 25 | 1.02× | 1.09× | ||
| Q2 25 | 0.60× | 0.95× | ||
| Q1 25 | 1.31× | 8.20× | ||
| Q4 24 | 1.30× | 2.35× | ||
| Q3 24 | 0.84× | 1.22× | ||
| Q2 24 | 0.60× | 0.99× | ||
| Q1 24 | 1.68× | 3.00× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HALO
| Royalty | $258.0M | 57% |
| Products | $122.7M | 27% |
| Proprietary Products Sales | $59.6M | 13% |
| Device Partnered Products | $12.9M | 3% |
NBIX
| INGREZZA Net Product Sales | $653.8M | 81% |
| CRENESSITY Net Product Sales | $135.4M | 17% |
| Other Income | $12.6M | 2% |
| Collaboration Revenue | $7.2M | 1% |
